Physician profile

Omana Abraham

Pediatrics (Nurse Practitioner) · Dallas, TX

NPI 1932294634

$708.19

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$95.54

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $189.21 2021-2022
Janssen Biotech, INC. $158.11 2021-2022
Takeda Pharmaceuticals U.S.A., INC. $115.15 2021-2022
Qol Medical, LLC $110.86 2021-2023 Sucraid
Nestle Healthcare Nutrition INC. $44.98 2021
Regeneron Healthcare Solutions, INC. $32.28 2023 Dupixent
Amgen INC. $22.00 2022
Lilly USA, LLC $21.91 2023 Mounjaro
Cumberland Pharmaceuticals, INC. $13.69 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Omana Abraham

$708.19

in general payments reported 2019-2025

Years
2021-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/11147334/omana-abraham

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.